Radius Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

On January 6, 2021, Radius Health, Inc. (Nasdaq: RDUS) announced that CEO Kelly Martin will present a virtual corporate update at the 39th Annual J.P. Morgan Healthcare Conference on January 13 at 9:10 a.m. EST. A live webcast can be accessed through the Investors section of Radius' website, with a replay available for 90 days post-presentation.

Radius is a biopharmaceutical company focused on endocrine therapeutics, with its lead product TYMLOS approved for treating high-risk osteoporosis in postmenopausal women. The company is also exploring treatments for men with osteoporosis and hormone-receptor positive breast cancer.

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Kelly Martin, President and CEO will present a virtual corporate update at the 39^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13 at 9:10 a.m. EST.

A live webcast of the presentation will be available by visiting the Investors section of Radius’ website at https://ir.radiuspharm.com/events-and-presentations. A replay of the webcast will be archived on Radius’ website for 90 days following the presentation.

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes the investigational use of abaloparatide injection for the treatment of men with osteoporosis, an investigational abaloparatide-patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer out-licensed to Menarini Group. For more information, please visit www.radiuspharm.com 

Investor & Media Relations Contact:
Peter Schwartzman
Email: investor-relations@radiuspharm.com
Phone: (617) 583-2017

FAQ

When will Radius Health present at the J.P. Morgan Healthcare Conference?

Radius Health will present at the J.P. Morgan Healthcare Conference on January 13, 2021, at 9:10 a.m. EST.

How can I watch the Radius Health conference presentation?

You can watch the Radius Health conference presentation via a live webcast on their Investors website.

What is Radius Health's lead product?

Radius Health's lead product is TYMLOS (abaloparatide) injection, approved for treating postmenopausal women with osteoporosis at high risk for fracture.

What other products are in Radius Health's pipeline?

Radius Health's pipeline includes treatments for men with osteoporosis, an abaloparatide-patch for osteoporosis, and elacestrant (RAD1901) for hormone-receptor positive breast cancer.

How long will the webcast of the Radius Health presentation be available?

The webcast of the Radius Health presentation will be available for replay for 90 days after the event.